🔗 Share this article

As the United States continues making historic changes to its immunization schedules, an unexpected name appears in a surprising turn: Høeg, a Danish American physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus shots during the global health crisis and has concentrated on possible fatalities following COVID-19 immunization in her recent tenure at the FDA.

Planned Changes to Pediatric Immunization Schedule

Agency leaders planned to reveal major changes to the pediatric immunization program in December, aligning the US with Denmark’s vaccine program, according to reports – a significant shift that would put the US out of alignment with many the global community with insufficient data for public health gain. This reveal has been postponed until the next year.

Instead of the top vaccines chief, Høeg is scheduled to present at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to head the office this year.

A Shift at the FDA

The acting appointment could signify a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Prasad solidify control at the FDA – and it points to a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting certain pediatric immunization guidelines in the US in order to be more similar to the Danish model, a society with universal health coverage and a population approximately the population of the state of Wisconsin.

To date public appearances, she has kept her attention on immunizations – traditionally the domain of Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Expertise

The appointee has little discernible background in medication creation, oversight or management, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for running the CDER, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in managing a large organization. She is not an expert in drug approvals.”

Past heads of CBER would “be deeply familiar with laws and regulations and the science of medication creation”, said Dr. Janet Woodcock. “Clearly, she lacks the kind of background that previous people who led CBER have had.”

The drug center has an enormous workload at the agency, the former commissioner emphasized.

“Many people just pays attention on the innovative therapies, but the generic program clears a multitude of generic medications. There’s a biologic copycat branch, non-prescription drug unit and other areas, and all of those need to be managed,” she noted. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a major management element to the job, which manages in excess of 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” the former official concluded.

Official Statement and Disputed Policies

In response to inquiries about Høeg’s fitness for the role and whether this appointment signifies more teamwork among regulatory chiefs on immunizations, a representative stated that the “inquiries are based on incorrect assumptions”.

“This background matches the responsibilities of her job,” the representative said, citing the months Dr. Høeg spent advising the agency head on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a disputed rapid drug-approval program that apparently troubled her preceding directors. “By what process are these drugs being picked for this voucher program? Who takes the choices?” Howard asked. “There is a lot of secrecy occurring at the FDA right now.”

In general, he said, “the FDA seems to be moving towards laxer rules of all drugs, with the exception of shots.”

Public History on Immunizations

With vaccines, Høeg has a clearer, if problematic, past, Howard observe. She authored a research paper using unconfirmed crowd-sourced reports to determine the frequency of heart inflammation following COVID-19 immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the current administration encompassed revising guidelines for recently developed shots and halting “optional” immunizations, she stated post-election on a audio program. At the FDA, Høeg has reportedly suggested excluding teenage boys from receiving COVID-19 vaccinations.

“She is an complete ideologue who begins with her conclusions and works backwards to fit the data in a extremely misleading, dishonest manner,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Høeg joined other dissenters, {like|